BLA 761211 · Immedica Pharma Ab
Loargys
Pegzilarginase-Nbln · Injection
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanCDER novel approval, Feb 23, 2026: To treat hyperarginemia in adults and pediatric patients two years and older with Arginase 1 Deficiency, in conjunction with dietary protein restriction
Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Feb 23, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
5
3 Phase 3, 0 recruiting
FAERS reports
31
23 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: HYPERSENSITIVITY REACTIONS INCLUDING ANAPHYLAXIS Patients treated with enzyme replacement therapies have experienced life-threatening hypersensitivity reactions, including anaphylaxis. Anaphylaxis has occurred during the early course of enzyme replacement therapy and after extended duration of therapy. Initiate LOARGYS in a healthcare setting with appropriate medical monitoring and support measures, including access to cardiopulmonary resuscitation equipment. If a severe hypersensitivity reaction (e.g. anaphylaxis) occurs, discontinue LOARGYS and immediately initiate appropriate medical treatment, including use of epinephrine. Inform patients of the symptoms of life-threatening hypersensitivity reactions, including anaphylaxis and to seek immediate medical care should symptoms occur [see Warnings and Precautions ( 5.1 )] . WARNING: HYPERSENSITIVITY REACTIONS INCLUDING...
What it is approved for
From the label in effect Feb 23, 2026.
LOARGYS is indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. This indication is approved under accelerated approval based on reduction of plasma arginine [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. LOARGYS is an arginine specific enzyme indicated for the treatment of hyperargininemia in adult and pediatric patients 2 years of age and older with Arginase 1 Deficiency (ARG1-D), in conjunction with dietary protein restriction. ( 1 ) This indication is approved under accelerated approval based on reduction of plasma arginine. ( 14 ) Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 1 )
Mechanism: ARG1-D is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. LOARGYS provides an exogenous source of the deficient human arginase 1 enzyme activity in patients with ARG1-D and reduces plasma arginine by converting it to urea and ornithine.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 23, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanLetterLabelReview
1 products under this application
- LOARGYS · PEGZILARGINASE-NBLN 0.1MG/KG · Injectable, Injection · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Pegzilarginase" as an intervention, any sponsor and status, largest first.
Immedica Pharma ABIndustry
NCT03371979 · 42 participants · Start Dec 21, 2017 · Primary completion Jun 11, 2020
Drug: Pegzilarginase; Pembrolizumab · For: Small-cell Lung Cancer
Sites: Mobile, Alabama; Aurora, Colorado; Denver, Colorado · 22 sites in all
- Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 DeficiencyPivotal-lookingCompleted
Immedica Pharma ABIndustry
NCT03921541 · 32 participants · Start May 1, 2019 · Primary completion Feb 1, 2023
Drug: Pegzilarginase; Placebo · For: Arginase I Deficiency; Hyperargininemia
Sites: Rogers, Arkansas; Orange, California; Stanford, California · 32 sites in all
Immedica Pharma ABIndustry
NCT03378531 · 14 participants · Start Dec 7, 2017 · Primary completion Dec 15, 2022
Drug: AEB1102 · For: Arginase I Deficiency; Hyperargininemia
Sites: Stanford, California; Gainsville, Florida; New York, New York · 7 sites in all
- Pegzilarginase in Subjects <24 Months Old With Arginase 1 DeficiencyPivotal-lookingCompleted
Immedica Pharma ABIndustry
NCT06582524 · 3 participants · Start Aug 30, 2024 · Primary completion Jun 17, 2025
Drug: Pegzilarginase · For: Arginase 1 Deficiency
Sites: Graz, Austria; Lisbon, Portugal; Bradford, United Kingdom
- A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 DeficiencyPivotal-lookingTerminated
Aeglea BiotherapeuticsIndustry
NCT05676853 · 3 participants · Start Apr 4, 2023 · Primary completion Apr 27, 2023
Drug: Pegzilarginase · For: Arginase I Deficiency; Hyperargininemia
Sites: Toronto, Canada
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hyperammonaemia12
- ammonia increased8
- decreased appetite5
- vomiting5
- pyrexia4
- somnolence4
- hyperammonaemic crisis3
- amino acid level increased2
- aphthous ulcer2
- arginine level decreased2
- asthenia2
- coma2
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2025 | 1 |
| 2026 | 30 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency.
Diaz GA, Schulze A, McNutt MC, et al. · J Inherit Metab Dis 2021 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Long-Term Efficacy and Tolerability of Pegzilarginase in Arginase 1 Deficiency: Results of Two International Multicentre Open-Label Extension Studies.
McNutt M, Rutsch F, Russo RS, et al. · J Inherit Metab Dis 2025 · Multicenter Study, Randomized Controlled Trial
- Epidemiology, methods of diagnosis, and clinical management of patients with arginase 1 deficiency (ARG1-D): A systematic review.
Bin Sawad A, Jackimiec J, Bechter M, et al. · Mol Genet Metab 2022 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Immedica Pharma Ab
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.